Results of a 1-year randomized controlled trial investigating treatment for diabetic macular edema (DME) show that intravitreal ziv-aflibercept (Zaltrap, Sanofi Genzyme) 1.25 or 2.5 mg is safe, according to Masoud Soheilian, MD.
In addition, when compared with intravitreal bevacizumab (Avastin, Genentech), it provides significantly greater improvement in best-corrected visual acuity (BCVA) with a lower dosing burden, said Dr. Soheilian, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
The double-blind study also found that the functional benefit of ziv-aflibercept over bevacizumab was particularly seen in eyes with BCVA ≤20/50.
Anatomical data showed that ziv-aflibercept 2.5 mg was associated with significantly greater reduction in central macular thickness (CMT) compared with both the lower dose of ziv-aflibercept and bevacizumab.
“DRCR.net Protocol T demonstrated that intravitreal aflibercept (Eylea, Regeneron) was more effective than bevacizumab and ranibizumab (Lucentis, Genentech) for improving vision in DME patients with baseline BCVA ≤ 20/50,” Dr. Soheilian said.